Second-Line Immunotherapy in Advanced Non-Driver NSCLC – Targeted Oncology
OncLive |
Second-Line Immunotherapy in Advanced Non-Driver NSCLC
Targeted Oncology Benjamin P. Levy, MD: We now have 3 drug approvals for second-line non–small cell lung cancer, with immunotherapy. We've got single-agent pembrolizumab, single-agent nivolumab, and single-agent atezolizumab, all showing superior outcomes when compared … Shifting NSCLC Landscape Creates Confusion for PD-1/Chemo Combo |
